Also, the incidence of benign, sarcoma and hematopoietic tumors was not significantly different when comparing Pot1a+/+ with Pot1a+/ki mouse cohorts in none of the p53 background (S7C–S7E Fig). This evidence concerns the gene PSME3 and sarcoma.